Popular Trials
Orthopedic Implant
Episealer Knee System vs Microfracture Surgery for Osteoarthritis
Recruiting0 awards10 criteria
Tempe, Arizona
This trial is testing a knee implant called the Episealer Knee System on patients with specific knee damage causing pain or disability. The implants aim to repair the damaged areas, improving knee function and reducing pain.
GLP-1 Receptor Agonist
NNC0194-0499, Cagrilintide, and Semaglutide for Alcoholic Liver Disease
Recruiting0 awardsPhase 2
Chandler, Arizona
This trial will investigate how three different medications, NNC0194-0499, cagrilintide, and semaglutide, affect liver damage and alcohol use in people with alcoholic liver
Tyrosine Kinase Inhibitor
Crizotinib for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Near-infrared Spectroscopy (NIRS) Monitor for Congenital Heart Disease
Recruiting1 award1 criteria
Phoenix, Arizona
Clinical studies are required to validate the hepatic NIRS monitor with other regional and global hemodynamic parameters and to evaluate its clinical use for continuous non-invasive hemodynamic monitoring. Using newer NIRS sensors the correlation between hepatic regional oxygen saturation and hepatic venous oxygen saturation (SvHO2) needs to be determined. If found to correlate then the NIRS can be used to evaluate early liver transplant failure and/or hepatic artery thrombosis, used as an early marker for shock, and necrotizing enterocolitis, and finally used in the outpatient setting to evaluate patients with chronic liver pathologies. If our validation study finds that NIRS monitors are an appropriate marker of hepatic venous saturation then it will lead to further clinical studies.
Popular Filters
Phase 3 Trials
RNA-targeted therapy
Lepodisiran for Cardiovascular Disease
Recruiting1 awardPhase 3
Phoenix, Arizona
This trial is testing lepodisiran, a medication given as an injection under the skin. It targets people with high levels of lipoprotein(a) who have cardiovascular disease or are at risk of heart attack or stroke. The medication works by lowering lipoprotein(a) levels to reduce the risk of these cardiovascular events.
Monoclonal Antibodies
Ranibizumab for Age-Related Macular Degeneration
Recruiting2 awardsPhase 3
Phoenix, Arizona
Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor \[VA\]-masked), active-comparator study designed to assess the efficacy, safety, and pharmacokinetics (PK) of 100mg/ml delivered via the Port Delivery System with ranibizumab (PDS) compared with ranibizumab intravitreal injections at 0.5 mg (10 mg/mL) in participants with neovascular age-related macular degeneration (nAMD).
Opioid Partial Agonist
Buprenorphine for Chronic Pain
Recruiting3 awardsPhase 3
Phoenix, Arizona
This is a Phase III, placebo-controlled, multicenter study with an enriched-enrollment withdrawal (EEW) design to evaluate the efficacy and safety of CAM2038 in opioid-experienced subjects with moderate to severe CLBP that requires continuous, around-the-clock (ATC) opioid treatment ≥ 40 mg morphine equivalent dose (MED). The study includes 5 phases: A Screening Phase (up to 2 weeks), a Transition Phase (up to 2 weeks), an Open-Label Titration Phase (up to 10 weeks), a Double-Blind Treatment Phase including a Final Study Visit (12 weeks), and a Follow-up Phase (4 weeks). The overall duration of participation in the core phase of the study (randomized Double-Blind Phase) is up to 30 weeks, from the Screening Phase through the Follow-up Phase. Subjects who complete the Double-Blind Treatment Study Phase will be offered an opportunity to continue treatment in an open label safety extension for up to 60 weeks. Additional subjects may be recruited to open label safety extension to meet the goal of 100 subjects with 60 weeks of treatment.
Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
Saxagliptin +2 More for Type 2 Diabetes
Recruiting3 awardsPhase 3
Phoenix, Arizona
The purpose of this study is to learn if BMS-477118 (Saxagliptin) as part of a triple combination therapy can improve (decrease) hemoglobin A1c in patients with type 2 diabetes after 24 weeks of treatment compared to a 2 drug oral antidiabetic therapy. The safety of this treatment will also be studied.
Trials With No Placebo
Monoclonal Antibodies
Ranibizumab for Age-Related Macular Degeneration
Recruiting2 awardsPhase 3
Phoenix, Arizona
Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor \[VA\]-masked), active-comparator study designed to assess the efficacy, safety, and pharmacokinetics (PK) of 100mg/ml delivered via the Port Delivery System with ranibizumab (PDS) compared with ranibizumab intravitreal injections at 0.5 mg (10 mg/mL) in participants with neovascular age-related macular degeneration (nAMD).
Combination Hormone Contraceptive
Norethindrone acetate/ethinyl estradiol for Birth Control
Recruiting4 awardsPhase 3
Phoenix, Arizona
This is a non-comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product.
Implant
MINIject™ Implant for Glaucoma
Recruiting1 award
Glendale, Arizona
This trial is testing a small device called the MINIject™ implant, which is designed to help lower eye pressure in people with primary open-angle glaucoma. The device works by making it easier for fluid to drain from the eye, reducing pressure and potentially preventing vision loss.
Quality-of-Life Assessment for COVID-19
Recruiting1 award10 criteria
Phoenix, Arizona
This study collects blood samples, medical information, and medical images from patients who are being treated for cancer and have a positive test for SARS CoV-2, the new coronavirus that causes the disease called COVID-19. Collecting blood samples, medical information, and medical images may help researchers determine how COVID-19 affects the outcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.
Aromatase Inhibitor
Letrozole +/- Chemotherapy for Ovarian Cancer
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing whether Letrozole, with or without Paclitaxel and Carboplatin, can effectively treat patients with Stage II-IV Low-Grade Serous Carcinoma of the ovary, fallopian tube, or peritoneum.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.